ArticleFrontiers in medicine2025
Red yeast rice-induced severe rhabdomyolysis complicated by acute kidney injury and respiratory failure: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red yeast rice (RYR), a commonly used supplement with statin-like properties, is generally considered safe but may cause severe adverse effects such as rhabdomyolysis. We report a rare case of severe RYR-induced rhabdomyolysis complicated by acute kidney injury (AKI) and respiratory failure, with diaphragmatic dysfunction as a key contributing factor. A 78-year-old woman developed progressive proximal muscle weakness, dyspnea, and tea-colored urine after taking RYR (2 g/day) for 1 month. She rapidly progressed to respiratory failure requiring intubation and mechanical ventilation. Laboratory tests showed a peak creatine kinase (CK) of 112,985 U/L, serum myoglobin (>3,000 μg/L), and AKI. Bedside ultrasound demonstrated diaphragmatic dysfunction, while electromyography (EMG) revealed preserved nerve conduction. Myositis-specific and paraneoplastic antibody panels were negative. She received continuous renal replacement therapy (CRRT), plasma exchange (PE), hemoperfusion (HP), and supportive care. During hospitalization, she developed deep vein thrombosis (DVT), pneumonia, and ileus, all of which resolved with treatment. At discharge, she had been weaned from mechanical ventilation and had partially recovered renal and muscle function. At follow-up, she was stable, ambulating, and performing daily functions without symptom recurrence. Although her initial presentation mimicked immune-mediated necrotizing myopathy (IMNM), the absence of myositis-specific antibodies and clinical improvement without immunosuppressive therapy supported a diagnosis of toxic rhabdomyolysis. This case highlights the importance of recognizing supplement-related toxicity and initiating timely organ-targeted supportive care. This appears to be the first reported case of RYR-induced rhabdomyolysis complicated by both AKI and respiratory failure from diaphragmatic dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.